![](https://endpts.com/wp-content/uploads/2022/10/Michael-Goldberg-Surge-tile.jpg)
Michael Goldberg, Surge Therapeutics CEO
Backed by Bob Langer, former Harvard prof sets out to test a new way to deliver I/O drugs — during surgery
Every year, millions of cancer patients undergo surgery to get their tumors removed. But while resection can stave off cancer for some time, as many …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.